Generic Medicine Info
Indications and Dosage
Adult: 200-300 mg daily in 2-3 divided doses, up to 600 mg daily if tolerated.
Elderly: Initial 100 mg daily, increase very carefully if necessary.
Renal Impairment
Initial 100 mg daily, increase very carefully if necessary.
Hepatic Impairment
Initial 100 mg daily, increase very carefully if necessary.
Lactation. Porphyria, recent MI.
Special Precautions
Pregnancy. Hepatic or renal impairment; CV disease; epilepsy. Monitor closely until depression improves due to suicidal risk in depressed patients. Withdraw gradually to reduce withdrawal symptoms. May precipitate migraine attacks. May impair ability to drive or operate machinery. Stop 48 hr before general anaesthesia.
Adverse Reactions
Headache, nausea, vomiting, drowsiness, tremor, ataxia, antimuscarinic side effects (e.g. dry mouth, constipation); musculoskeletal pain; mild hypertension; skin rashes; convulsions; jaundice. Increase in LFT.
Drug Interactions
May decrease antihypertensive effects with antihypertensives. Increased CNS depressant effects with alcohol. Increased the anticoagulant effects of acenocoumarol.
Potentially Fatal: Increased carbamazepine, theophylline, aminophylline, phenytoin levels and thus increased risk of toxicity. Do not admin viloxazine for at least 14 days after discontinuation from MAOI and MAOI to be given at least 1 wk after discontinuation from viloxazine.
Description: Viloxazine, a bicyclic antidepressant, inhibits noradrenaline reuptake and enhance serotonin release from neuronal stores. It has fewer antimuscarinic side effects compared to tricyclic antidepressants.
Absorption: Absorbed readily from GI tract.
Distribution: Distributed in breastmilk.
Metabolism: Extensively metabolised. Plasma half life: 2-5 hr.
Excretion: Excreted in urine as free or conjugated metabolites.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Viloxazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in